Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Semaglutide improves liver health and lipid levels in diabetes
Last updated July 22, 2026
Key finding
BMI decreased from 33.06 ± 2.1 kg/m² at baseline to 29.92 ± 3.15 kg/m² at 12 months (p < 0.001).
This study evaluated the effects of semaglutide on lipid profiles and liver parameters in patients with type 2 diabetes and obesity, showing significant improvements.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of semaglutide on lipid profiles and liver parameters in patients with type 2 diabetes and obesity, showing significant improvements.
Clinical relevance
These findings are clinically significant as they suggest that semaglutide not only aids in weight loss but also improves liver function and lipid levels, which are critical factors in managing type 2 diabetes and preventing related complications. This could lead to better overall health outcomes for patients with obesity and diabetes.
Keep in mind
Non-randomized design limits causal inference Sample size and demographic diversity not specified Effectiveness unclear for all interventions
Published in
Journal Reference
Publication details and source links for this paper.
Ahmed IG, Nevin FI, Noura A, et al. Semaglutide Improves Lipid Profile and Liver Parameters in Patients with Type 2 Diabetes and Obesity. Diseases. 2024;12(8):186. doi:10.3390/diseases12080186
Main Effects
BMI decreased from 33.06 kg/m² to 29.92 kg/m² (p < 0.001)
HDL increased from 45.6 mg/dL to 50.08 mg/dL (p < 0.001)
Liver stiffness measurement decreased significantly (p < 0.001)
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Pioglitazone, Semaglutide, Subcutaneous Semaglutide and BMI, AST, Alanine Aminotransferase (ALT), and 8 more.
This study contributes evidence to
Primary intervention
Pioglitazone
Primary outcomes
- BMI
- AST
- Alanine Aminotransferase (ALT)
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
13
Evidence pairs
13
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
13
Evidence pairs
438
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 13 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Mass Index
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Adipokine and Angiogenic Markers
Save evidence
Evidence relationship
Thiazolidinediones and Body Mass Index
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Alanine Aminotransferase (ALT)
Semaglutide → Alanine Aminotransferase (ALT)
Semaglutide → Alanine Aminotransferase (ALT)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 75
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerControlled attenuation parameter
Subcutaneous Semaglutide → Controlled attenuation parameter
Subcutaneous Semaglutide → Controlled attenuation parameter
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerLiver stiffness measure
Subcutaneous Semaglutide → Liver stiffness measure
Subcutaneous Semaglutide → Liver stiffness measure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- BMI decreased by 3.14 kg/m² (p < 0.001)
- HDL increased by 4.48 mg/dL (p < 0.001)
- Liver enzymes (AST and ALT) decreased significantly
Who this applies to
- Adults with type 2 diabetes
- Individuals with obesity
- Patients seeking metabolic health improvement
Keep in Mind
- Results may not generalize to non-obese populations
- Long-term effects beyond 12 months are unknown
- Further studies needed to confirm findings
Between the Lines
- Non-randomized design limits causal inference
- Sample size and demographic diversity not specified
- Effectiveness unclear for all interventions
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Mass Index, Thiazolidinediones and Body Mass Index.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 75
- consistent
Supporting studies: Based on 4 studies
View evidenceMedications
Thiazolidinediones → Body Mass Index
Medications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 75
- Positive
- ConsistencyScore™
- 35
- mixed
Supporting studies: Based on 2 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Mass Index Evidence Hub
All studies measuring Body Mass Index
4 studies
outcome_hubMeasures Body Mass Index as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
4 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Adipokine and Angiogenic Markers Evidence Hub
All studies measuring Adipokine and Angiogenic Markers
2 studies
outcome_hubMeasures Adipokine and Angiogenic Markers as a key outcome.
Thiazolidinediones Evidence Hub
All studies on Thiazolidinediones
2 studies
intervention_hubContributes to Thiazolidinediones evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and BMI
Intervention: SemaglutideOutcome: BMI
4 results
All studies on Pioglitazone and BMI
Intervention: PioglitazoneOutcome: BMI
2 results
All studies on Semaglutide
Intervention: Semaglutide
4 results
All studies on Pioglitazone
Intervention: Pioglitazone
2 results
All studies measuring BMI
Outcome: BMI
4 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body mass index?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 15 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve adipokine and angiogenic markers?
Strong Evidence
GLP-1 Receptor Agonists may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
LDL cholesterol
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
- 2
Alanine Aminotransferase (ALT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 3
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Thiazolidinediones affect body mass index?
Moderate Evidence
Thiazolidinediones appears to improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
BMI
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Does Semaglutide improve nafld fibrosis score?
Moderate Evidence
Semaglutide may improve NAFLD Fibrosis Score.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Evidence caveat: The available evidence reports mixed findings.
Ranked evidence signals
- 1
NAFLD Fibrosis Score
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
- Only one supporting study is available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide improves vascular and liver function in type 2 diabetesSemaglutide may reduce cardiovascular events in non-diabetic patients.Mediterranean ketogenic eating matched VLCKD for weight loss over 3 monthsOral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.